CHM — Chimeric Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$21.05m
- AU$20.16m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.064 | 15.1 | 15.7 | 25.4 |
Operating Profit | -0.064 | -15.1 | -15.7 | -25.4 |
Net Income Before Taxes | -0.064 | -15.1 | -15.7 | -25.4 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.064 | -15.1 | -15.9 | -25.5 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.064 | -15.1 | -15.9 | -25.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.064 | -15.1 | -15.9 | -25.5 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0 | -0.08 | -0.044 | -0.059 |
Dividends per Share |